Neumora Therapeutics Income Statement (2022-2026) | NMRA

Income Statement Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Operating items
Research & Development (Quarter) 22.55M23.52M29.48M32.77M41.60M38.86M45.76M48.63M60.63M45.91M52.15M38.72M40.52M44.67M38.60M
Selling, General & Administrative (Quarter) 8.05M7.20M9.68M9.29M15.26M11.24M14.32M15.19M16.02M17.01M18.79M15.32M12.18M13.81M14.27M
Other Operating Expenses (Quarter) 63.90M5.00M
Operating Expenses (Quarter) 30.60M30.72M39.17M42.06M56.86M114.00M60.07M63.82M76.65M62.92M70.94M54.04M57.70M58.48M52.86M
Operating Income (Quarter) -30.60M-30.72M-39.17M-42.06M-56.86M-114.00M-60.07M-63.82M-76.65M-62.92M-70.94M-54.04M-57.70M-58.48M-52.86M
EBIT (Quarter) -30.60M-30.72M-39.17M-42.06M-56.86M-114.00M-60.07M-63.82M-76.65M-62.92M-70.94M-54.04M-57.70M-58.48M-52.86M
Non-operating items
Interest & Investment Income (Quarter) -0.28M0.38M0.48M-0.15M0.14M0.23M-0.07M-0.04M4.21M4.09M-0.07M-0.01M1.69M-0.01M
Other Non Operating Income (Quarter) -0.15M0.29M-0.03M-0.04M-0.00M-0.10M-0.01M-0.02M-0.06M0.01M-0.03M-0.48M0.01M4.87M0.06M
Non Operating Income (Quarter) 1.26M2.17M3.57M3.56M3.84M5.54M6.35M5.25M4.15M4.10M3.05M1.33M0.94M-0.97M-0.56M
Net income details
EBT (Quarter) -30.89M-171.90M-38.69M-38.54M-53.03M-108.46M-53.72M-58.58M-72.49M-58.81M-67.89M-52.71M-56.76M-59.45M-53.43M
Tax Provisions (Quarter) 0.12M0.05M0.10M0.03M-0.05M0.03M
Profit After Tax (Quarter) -29.63M-28.92M-35.62M-38.54M-53.03M-109.19M-53.72M-58.70M-72.55M-58.68M-68.06M-52.73M-56.76M-59.46M-53.46M
Income from Continuing Operations (Quarter) -30.89M-171.90M-38.69M-38.54M-53.03M-108.46M-53.72M-58.70M-72.55M-58.81M-67.99M-52.73M-56.76M-59.40M-53.46M
Consolidated Net Income (Quarter) -30.89M-171.90M-38.69M-38.54M-53.03M-108.46M-53.72M-58.70M-72.55M-58.81M-67.99M-52.73M-56.76M-59.40M-53.46M
Income towards Parent Company (Quarter) -30.89M-171.90M-38.69M-38.54M-53.03M-108.46M-53.72M-58.70M-72.55M-58.81M-67.99M-52.73M-56.76M-59.40M-53.46M
Net Income towards Common Stockholders (Quarter) -30.89M-171.90M-38.69M-38.54M-53.03M-108.46M-53.72M-58.70M-72.55M-58.81M-67.99M-52.73M-56.76M-59.40M-53.46M
Additional items
EPS (Basic) (Quarter) -1.12-6.32-1.32-1.28-1.14-1.67-0.34-0.37-0.45-0.37-0.42-0.33-0.35-0.36-0.30
EPS (Diluted) (Quarter) -1.12-6.32-1.32-1.28-1.14-1.67-0.34-0.37-0.45-0.37-0.42-0.33-0.35-0.36-0.30
Shares Outstanding (Quarter) 27.65M27.21M29.28M30.12M46.69M65.02M157.94M158.98M159.58M159.38M161.45M161.69M161.84M163.39M179.87M
Shares Outstanding (Diluted) (Quarter) 27.65M27.21M29.28M30.12M46.69M65.02M157.94M158.98M159.58M159.38M161.45M161.69M161.84M163.39M179.87M
EBITDA (Quarter) -30.60M-30.72M-39.17M-42.06M-56.86M-114.00M-60.07M-63.82M-76.65M-62.92M-70.94M-54.04M-57.70M-58.48M-52.86M
Interest Expenses (Quarter) 141.56M113.85M146.97M90.74M43.67M72.96M1.10M1.00M2.04M1.85M
Tax Rate (Quarter) -0.21-0.07-0.15-0.050.08-0.06